ipilimumab
bms
['improve ', 'melanoma']
tumour-infiltrating lymphocytes improve pfs (7.2 months versus 3.1 months) in advanced melanoma even in patients who are refractory to anti-pd-1 treatment 
Professor of Medical Oncology,  Amrita Institute of Medical  Sciences. Oncologist and Hematologist